This is the first episode of a four-part series, “Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD,” supported by an educational grant from Arcutis. In this episode, “Steroidal vs Non-Steroidal Topicals – Case by Case Discussion,” expert dermatologists, Mona Shahriari, MD and James Song, MD, discuss:

• Appropriate use of topical corticosteroids and targeted topicals for atopic dermatitis
• Benefits of topical corticosteroids and remaining unmet needs
• How new targeted topicals fit into the atopic dermatitis toolbox and improve adherence to therapy
• Case-based discussion of targeted topicals for the treatment of AD.

In this episode, entitled “JAK Inhibition for Treatment of Vitiligo,” expert dermatologists, Dr Andrew Alexis, MD, MPH and Dr Erik Domingues, MD, FAAD, discuss the following topics: ·       Changing the culture of vitiligo care ·       Diagnosing vitiligo and associated comorbidities ·       Strategies for managing vitiligo and educating patients about treatment options ·       Setting patient expectations for the treatment process

This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics:

• Mechanism of action for IL-31 inhibitor nemolizumab

• Clinical safety and efficacy data for nemolizumab for treatment of PN

• Strategies for prescribing IL-31 inhibitors in clinical practice

• Pearls for patient selection and addressing treatment challenges

This is the second episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, is joined by Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford University School of Medicine in Stanford, CA, as they discuss the following topics:

• Setting the stage for treating a patient with EB

• Assessing EB severity and subtype to inform treatment

• Expert review of the current FDA-approved treatments and

• Strategies to close care gaps for EB patients

This is the sixth episode of our ongoing "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?", featuring Beth Sweney, PA-C discusses the following topics:

1. Challenges in achieving treatment targets in AD

2. Therapeutic inertia and clinical implications of inadequate response

3. Comparative clinical data evaluating upadacitinib and dupilumab for treatment of AD

4. Transitioning to systemic therapies from topical agents, immunosuppressives, and biologic therapies

This is the first episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford University School of Medicine in Stanford, CA, is joined by Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, as they discuss the following topics:

• Epidemiology and prevalence of EB

• Burden of disease and impact on patients' quality of life

• Gaps and challenges for patients with EB

• Assessing the current knowledge of clinicians and gaps in care recommendations

This podcast episode, sponsored by Leo Pharma, features LiVDerm faculty and esteemed dermatologists Dr. Christopher Bunick, MD, PhD, and Dr. Jonathan Silverberg, MD, PhD, MPH. As experts in all things concerning eczema, our faculty discuss the differentiating features and disease burden in patients suffering from chronic hand eczema (CHE) and review the current guidance for treatment, including these specific topics:

1. Differentiating CHE from atopic dermatitis of the hands, including triggers, pathophysiology, and clinical presentation

2. Expert guidance for accurate diagnosis and work-up of CHE patients

3. Challenges and limitations of current therapeutic offerings

4. The potential of a topical novel pan-JAK inhibitor for targeted treatment of CHE

This is the first episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma and hosted by prurigo nodularis (PN) expert Dr. Shawn Kwatra, MD. This episode, "Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis", featuring expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, discusses the following topics:

• The lack of awareness and timely, correct diagnosis of PN patients

• Strategies for assessing patients with PN and alleviating disease symptoms and burden

• Examining the current expert guidance and available therapies for treating PN

• Looking to the future of PN diagnosis and targeted treatment

This is the second episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "New Therapies and Expert Strategies for Long-term Control", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics:

1. The pros and cons of steroid use in treating AD

2. Targeted non-steroidal topical therapies approved by the FDA

3. Relevant clinical efficacy and safety data for new and emerging non-steroidal topicals

4. Recommendations for long-term symptom control in AD patients

This is the fifth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?", featuring expert dermatologist Dr. Naiem Issa, MD, PhD, discusses the following topics:

1. Mechanistic differences between JAKi and biologics for treatment of AD

2. Clinical data supporting the safety of JAKi in head-to-head trials compared to biologics

3. Pearls for prescribing JAKi to AD patients

4. Strategies for choosing JAKi vs biologics based on safety and patient factors